Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune system to fight cancer by enabling durable responses and preventing tumor recurrence
Finalizing preclinical package to initiate clinical studies in 2022
Preclinical Proof of Concept in cancer models including combination with checkpoint inhibitors
Seeking funding by life science investors and partnerships in oncology & infectious diseases
News & Events
Immunetune Establishes International Scientific Advisory Board LEIDEN, the Netherlands, January 11, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the appointment of...
Immunetune Announces Presentations at Industry Conferences during November 2021 LEIDEN, the Netherlands, November 2, 2021 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced...
BIO-Europe, 25-28 October 2021 Sijme Zeilemaker, CEO of Immunetune, will be attending BIO-Europe, taking place October 25-28, 2021, in digital format. Feel free to reach out to us to set up a meeting and explore collaboration and investment opportunities. E-mail:...